Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
PLoS One
2023 Jan 01;184:e0273138. doi: 10.1371/journal.pone.0273138.
Show Gene links
Show Anatomy links
Translation of immunomodulatory therapy to treat chronic heart failure: Preclinical studies to first in human.
Humes HD
,
Aaronson KD
,
Buffington DA
,
Sabbah HN
,
Westover AJ
,
Yessayan LT
,
Szamosfalvi B
,
Pagani FD
.
???displayArticle.abstract???
BACKGROUND: Inflammation has been associated with progression and complications of chronic heart failure (HF) but no effective therapy has yet been identified to treat this dysregulated immunologic state. The selective cytopheretic device (SCD) provides extracorporeal autologous cell processing to lessen the burden of inflammatory activity of circulating leukocytes of the innate immunologic system.
AIM: The objective of this study was to evaluate the effects of the SCD as an extracorporeal immunomodulatory device on the immune dysregulated state of HF. HF.
METHODS AND RESULTS: SCD treatment in a canine model of systolic HF or HF with reduced ejection fraction (HFrEF) diminished leukocyte inflammatory activity and enhanced cardiac performance as measured by left ventricular (LV) ejection fraction and stroke volume (SV) up to 4 weeks after treatment initiation. Translation of these observations in first in human, proof of concept clinical study was evaluated in a patient with severe HFrEFHFrEF ineligible for cardiac transplantation or LV LV assist device (LVAD) due to renal insufficiency and right ventricular dysfunction. Six hour SCD treatments over 6 consecutive days resulted in selective removal of inflammatory neutrophils and monocytes and reduction in key plasma cytokines, including tumor necrosis factor-alpha (TNF-α),), interleukin (IL)-6, IL-8, and monocyte chemoattractant protein (MCP)-1. These immunologic changes were associated with significant improvements in cardiac power output, right ventricular stroke work index, cardiac index and LVSV index…. Stabilization of renal function with progressive volume removal permitted successful LVAD implantation.
CONCLUSION: This translational research study demonstrates a promising immunomodulatory approach to improve cardiac performance in HFrEFHFrEF and supports the important role of inflammation in the progression of HFHF.
???displayArticle.pubmedLink???
37023139
???displayArticle.link???PLoS One ???displayArticle.grants???[+]
Adamo,
Reappraising the role of inflammation in heart failure.
2020, Pubmed
Adamo,
Reappraising the role of inflammation in heart failure.
2020,
Pubmed
Arruda-Olson,
Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study.
2009,
Pubmed
Ciarambino,
Cardiomyopathies: An Overview.
2021,
Pubmed
Conraads,
Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure.
2005,
Pubmed
Costanzo,
Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research.
2017,
Pubmed
Courties,
The innate immune system after ischemic injury: lessons to be learned from the heart and brain.
2014,
Pubmed
Deshmane,
Monocyte chemoattractant protein-1 (MCP-1): an overview.
2009,
Pubmed
Dick,
Chronic Heart Failure and Inflammation: What Do We Really Know?
2016,
Pubmed
Ding,
A biomimetic membrane device that modulates the excessive inflammatory response to sepsis.
2011,
Pubmed
Dirksen,
Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies.
2007,
Pubmed
Dixon,
Systemic inflammation and cell activation reflects morbidity in chronic heart failure.
2011,
Pubmed
Elchinova,
Circulating monocyte subsets and heart failure prognosis.
2018,
Pubmed
Elghetany,
Surface antigen changes during normal neutrophilic development: a critical review.
2002,
Pubmed
Fabiani,
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets.
2021,
Pubmed
Fincke,
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry.
2004,
Pubmed
Fumagalli,
The influence of age on the psychological profile of patients with cardiac implantable electronic devices: results from the Italian population in a multicenter study conducted by the European Heart Rhythm Association.
2019,
Pubmed
Goldstein,
Use of the Selective Cytopheretic Device in Critically Ill Children.
2021,
Pubmed
Humes,
Translation of immunomodulatory therapy to treat chronic heart failure: Preclinical studies to first in human.
2023,
Pubmed
Johnston,
Novel Leukocyte Modulator Device Reduces the Inflammatory Response to Cardiopulmonary Bypass.
2019,
Pubmed
Krahn,
Arrhythmogenic Right Ventricular Cardiomyopathy.
2022,
Pubmed
Kuijpers,
Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation.
1991,
Pubmed
Landmann,
Human monocyte CD14 is upregulated by lipopolysaccharide.
1996,
Pubmed
Leuschner,
Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction.
2010,
Pubmed
Lundahl,
Human blood monocytes, but not alveolar macrophages, reveal increased CD11b/CD18 expression and adhesion properties upon receptor-dependent activation.
1996,
Pubmed
Lynn,
Lipopolysaccharide-induced stimulation of CD11b/CD18 expression on neutrophils. Evidence of specific receptor-based response and inhibition by lipid A-based antagonists.
1991,
Pubmed
Mascia,
Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis.
2022,
Pubmed
Mendoza,
Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease.
2007,
Pubmed
Monneret,
The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration.
2004,
Pubmed
Murphy,
Inflammation in Heart Failure: JACC State-of-the-Art Review.
2020,
Pubmed
Nahrendorf,
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions.
2007,
Pubmed
Ochiai,
Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients.
2002,
Pubmed
Pino,
Regenerative Medicine and Immunomodulatory Therapy: Insights From the Kidney, Heart, Brain, and Lung.
2018,
Pubmed
Pino,
A selective cytopheretic inhibitory device for use during cardiopulmonary bypass surgery.
2012,
Pubmed
Pitt,
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
1999,
Pubmed
Ponikowski,
Heart failure: preventing disease and death worldwide.
2014,
Pubmed
Sabbah,
A canine model of chronic heart failure produced by multiple sequential coronary microembolizations.
1991,
Pubmed
Sager,
Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure.
2016,
Pubmed
Schenk,
Duration of inotropic support after left ventricular assist device implantation: risk factors and impact on outcome.
2006,
Pubmed
Simms,
Activated macrophages decrease rat cardiac myocyte contractility: importance of ICAM-1-dependent adhesion.
1999,
Pubmed
Smiley,
Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
2022,
Pubmed
Swirski,
Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure.
2013,
Pubmed
Swirski,
Identification of splenic reservoir monocytes and their deployment to inflammatory sites.
2009,
Pubmed
Szamosfalvi,
Immunomodulatory Device Promotes a Shift of Circulating Monocytes to a Less Inflammatory Phenotype in Chronic Hemodialysis Patients.
2016,
Pubmed
Tracchi,
Increased neutrophil lifespan in patients with congestive heart failure.
2009,
Pubmed
Tsujioka,
Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction.
2009,
Pubmed
Tumlin,
The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study.
2013,
Pubmed
Tumlin,
A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury.
2015,
Pubmed
Usher,
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
2010,
Pubmed
Vinten-Johansen,
Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury.
2004,
Pubmed
Walcheck,
Neutrophil rolling altered by inhibition of L-selectin shedding in vitro.
1996,
Pubmed
Wrigley,
CD14++CD16+ monocytes in patients with acute ischaemic heart failure.
2013,
Pubmed
Yessayan,
Treatment of Cytokine Storm in COVID-19 Patients With Immunomodulatory Therapy.
2020,
Pubmed
Yessayan,
Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients.
2022,
Pubmed
Yndestad,
Systemic inflammation in heart failure--the whys and wherefores.
2006,
Pubmed
van der Laan,
Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir.
2014,
Pubmed